NEWS

Tony Cates joins Cycle Group Holdings Board of Directors

October 6

2021

Holly Archer2021-10-06T10:39:32+01:00

Tony Cates joins Cycle Group Holdings Board of Directors

September 28

2021

Holly Archer2021-09-28T11:36:58+01:00

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

September 10

2021

Holly Archer2021-09-14T16:56:52+01:00

Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

June 28

2021

Kierah Bircham2021-06-28T11:44:17+01:00

Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer

May 25

2021

Holly Archer2021-05-25T17:41:24+01:00

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer

April 29

2021

Holly Archer2021-05-17T18:52:30+01:00

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

March 15

2021

Holly Archer2021-05-17T18:52:30+01:00

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

December 2

2020

Holly Archer2021-05-17T18:52:30+01:00

Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

October 19

2020

Web_Admin2021-05-17T18:52:30+01:00

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

September 14

2020

Holly Archer2021-05-17T18:52:30+01:00

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

September 8

2020

Holly Archer2021-05-17T18:52:31+01:00

Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors

September 8

2020

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

September 5

2020

web_admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Secures $25 Million Debt Financing

August 5

2020

Holly Archer2021-05-17T18:52:31+01:00

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

May 13

2020

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

May 5

2020

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

April 19

2020

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

March 13

2020

Web_Admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals’ Supply Chain update

December 18

2019

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

October 31

2019

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

April 28

2019

Holly Archer2021-05-17T18:52:31+01:00

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

November 22

2018

Web_Admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

November 19

2018

Holly Archer2021-05-17T18:52:31+01:00

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

November 12

2018

Holly Archer2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

August 29

2018

Web_Admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

August 29

2018

Web_Admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.

November 10

2017

Web_Admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

August 1

2017

web_admin2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

June 2

2017

Web_Admin2021-05-17T18:52:31+01:00

First recommendation for HT-1 treatment in Quebec by INESSS

December 19

2016

Web_Admin2021-05-17T18:52:31+01:00

CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

November 8

2016

Web_Admin2021-05-17T18:52:31+01:00

Our latest news and press releases.

Tony Cates joins Cycle Group Holdings Board of Directors

Tony Cates joins Cycle Group Holdings Board of Directors

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

Cycle Pharmaceuticals Secures $25 Million Debt Financing

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

Cycle Pharmaceuticals’ Supply Chain update

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

First recommendation for HT-1 treatment in Quebec by INESSS

CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1

FOLLOW US

ABOUT US

TECHNOLOGY PARTNERSHIPS